Document Detail

Menatetrenone for the treatment of osteoporosis.
MedLine Citation:
PMID:  23346882     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The effect of the anti-osteoporosis medicine, menatetrenone (vitamin K(2); menaquinone-4) on the skeleton remains a matter of controversy. The objective of the present review study was to evaluate the effect of menatetrenone on the skeleton of postmenopausal women, men and glucocorticoid-treated patients.
METHODS: PubMed was used to search the literature for randomized controlled trials (RCTs), meta-analyses and systematic reviews. Thirteen RCTs, one meta-analysis and one systematic review were available for analysis.
RESULTS: Except for one large Japanese RCT (Phase IV trial: Osteoporotic Fracture (OF) study, n = 4378), RCTs with small sample size showed non-significant or modest effect on bone mineral density (BMD) in postmenopausal women and patients treated with glucocorticoid, positive effect on hip geometry in postmenopausal women and efficacy against fractures (mainly vertebral fractures) in postmenopausal women with osteoporosis. A post hoc analysis of the OF study showed that the incidence of vertebral fractures decreased in postmenopausal women with at least five vertebral fractures. A meta-analysis study, but not a systematic review study, showed efficacy against vertebral and non-vertebral fractures mainly in postmenopausal women with osteoporosis. There was no available evidence for men with osteoporosis.
CONCLUSION: The present review of the literature revealed some evidence of a positive effect of menatetrenone on the skeleton of postmenopausal women and in patients treated with glucocorticoid.
EXPERT OPINION: Menatetrenone is considered to be a second-line medicine for postmenopausal osteoporotic women with an increased risk for vertebral fractures.
Jun Iwamoto; Yoshihiro Sato
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-25
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-26     Completed Date:  2013-08-12     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  449-58     Citation Subset:  IM    
Keio University School of Medicine, Institute for Integrated Sports Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density / drug effects*
Clinical Trials as Topic
Osteocalcin / metabolism
Osteoporosis / drug therapy*,  epidemiology,  etiology,  metabolism
Spinal Fractures / epidemiology,  prevention & control
Treatment Outcome
Vitamin K 2 / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
104982-03-8/Osteocalcin; 11032-49-8/Vitamin K 2; 27Y876D139/menatetrenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Infection-related hospital admissions after transrectal biopsy of the prostate.
Next Document:  The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosin...